Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful faithfully but unsuccessfully to develop a single therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last several shares. My 1st CytoDyn post, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away what follows prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a very promotional picture in the Uptick Newswire job interview which I came away with a bad viewpoint of the company.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, yet the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor of the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this expertise and also linked intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 huge number of) and the very first brand new drug program approval ($5 million), as well as royalty payments of 5 percent of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and many indications, it’s this individual remedy and a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an active company with diverse interests albeit centered on leronlimab, multiple disease types, multiple presentations and multiple publications.

Might all of it be smoke and mirrors? That’s a question I have been asking myself from the really start of my interest in this particular organization. Judging with the multiples of a huge number of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *